Analysis of PIK3CA Mutation Concordance and Frequency in Primary and Different Distant Metastatic Sites in Breast Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The purpose of this study was to investigate the concordance rate of <i>PIK3CA</i> mutations between primary and matched distant metastatic sites in patients with breast cancer and to verify whether there are differences in the frequency of <i>PIK3CA</i> hotspot mutations depending on the metastatic sites involved.Materials and Methods Archived formalin-fixed paraffin-embedded (FFPE) specimens of primary breast and matched distant metastatic tumors were retrospectively obtained for 49 patients. Additionally, 40 archived FFPE specimens were independently collected from different breast cancer metastatic sites, which were limited to three common sites: the liver, brain, and lung. <i>PIK3CA</i> mutations were analyzed using droplet digital PCR, including hotspots involving exons 9 and 20. Results After analysis of 49 breast tumors with matched metastasis sites, 87.8% showed concordance in <i>PIK3CA</i> mutation status. According to <i>PIK3CA</i> hotspot mutation testing in 89 cases of breast cancer metastatic sites, the proportion of <i>PIK3CA</i> mutations at sites of metastasis involving the liver, brain, and lung was 37.5%, 28.6%, and 42.9%, respectively, which did not result in statistical significance. Conclusion The high concordance of <i>PIK3CA</i> mutation status between primary and matched metastasis sites suggests that metastatic sites, regardless of the metastatic organ, could be considered sample sources for <i>PIK3CA</i> mutation testing for improved therapeutic strategies in patients with metastatic breast cancer.
Abstract
Purpose The purpose of this study was to investigate the concordance rate of <i>PIK3CA</i> mutations between primary and matched distant metastatic sites in patients with breast cancer and to verify whether there are differences in the frequency of <i>PIK3CA</i> hotspot mutations depending on the metastatic sites involved.Materials and Methods Archived formalin-fixed paraffin-embedded (FFPE) specimens of primary breast and matched distant metastatic tumors were retrospectively obtained for 49 patients. Additionally, 40 archived FFPE specimens were independently collected from different breast cancer metastatic sites, which were limited to three common sites: the liver, brain, and lung. <i>PIK3CA</i> mutations were analyzed using droplet digital PCR, including hotspots involving exons 9 and 20. Results After analysis of 49 breast tumors with matched metastasis sites, 87.8% showed concordance in <i>PIK3CA</i> mutation status. According to <i>PIK3CA</i> hotspot mutation testing in 89 cases of breast cancer metastatic sites, the proportion of <i>PIK3CA</i> mutations at sites of metastasis involving the liver, brain, and lung was 37.5%, 28.6%, and 42.9%, respectively, which did not result in statistical significance. Conclusion The high concordance of <i>PIK3CA</i> mutation status between primary and matched metastasis sites suggests that metastatic sites, regardless of the metastatic organ, could be considered sample sources for <i>PIK3CA</i> mutation testing for improved therapeutic strategies in patients with metastatic breast cancer.
참고문헌 (30)
- Pan H, "20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years", N Engl J Med, 377, pp.1836~1846 (2017)
- Gradishar WJ, "Breast cancer, version 3. 2020, NCCN Clinical Practice Guidelines in Oncology", J Natl Compr Canc Netw, 18, pp.452~478 (2020)
- Janku F, "Targeting the PI3K pathway in cancer : are we making headway?", Nat Rev Clin Oncol, 15, pp.273~291 (2018)
- Karakas B, "Mutation of the PIK3CA oncogene in human cancers", Br J Cancer, 94, pp.455~459 (2006)
- Ligresti G, "PIK3CA mutations in human solid tumors : role in sensitivity to various therapeutic approaches", Cell Cycle, 8, pp.1352~1358 (2009)
- Isakoff SJ, "Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells", Cancer Res, 65, pp.10992~11000 (2005)
- Mosele F, "Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer", Ann Oncol, 31, pp.377~386 (2020)
- Anderson EJ, "A systematic review of the prevalence and diagnostic workup of PIK3CA mutations in HR+", HER2-metastatic breast cancer, 2020, pp.2020, 3759179~
- Ling Deng, "Prevalence and Prognostic Role of PIK3CA", AKT1 Mutations in Chinese Breast Cancer Patients, 2019, pp.51(1), 128~140[DOI]
- inhibitor)plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer : interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study, "Ann Oncol", 2016, 2059~2066
- Krop IE, "Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer(FERGI) : a randomised, double-blind, placebo-controlled, phase 2 trial", Lancet Oncol, 17, pp.811~821 (2016)
- Baselga J, "Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer(BELLE-2) : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet Oncol, 18, pp.904~916 (2017)
- Di Leo A, "Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition(BELLE-3) : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet Oncol, 19, pp.87~100 (2018)
- Yang J, "Targeting PI3K in cancer : mechanisms and advances in clinical trials", Mol Cancer, 18, pp.26~ (2019)
- Andre F, "Alpelisib(ALP)+fulvestrant(FUL)for advanced breast cancer(ABC) : results of the phase III SOLAR-1 trial", Ann Oncol, 29(Suppl 8), pp.VIII709~ (2018)
- Allison KH, "Estrogen and progesterone receptor testing in breast cancer : ASCO", CAP guideline update, 2020, pp.38, 1346~1366
- Goldhirsch A, "Personalizing the treatment of women with early breast cancer : highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013", Ann Oncol, 24, pp.2206~2223 (2013)
- Andre F, "Alpelisib for PIK3CA-mutated, hormone receptorpositive advanced breast cancer", N Engl J Med, 380, pp.1929~1940 (2019)
- Cizkova M, "PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR and ERBB2-based subgroups", Breast Cancer Res, 14, pp.R28~ (2012)
- Campbell IG, "Mutation of the PIK3CA gene in ovarian and breast cancer", Cancer Res, 64, pp.7678~7681 (2004)
- "Summary of safety and effectiveness data of therascreen PIK3CA RGQ PCR kit" (2019)[URL]
- Zhu G, "Highly sensitive droplet digital PCR method for detection of EGFR-acti-vating mutations in plasma cell-free DNA from patients with advanced non-small cell lung cancer", J Mol Diagn, 17, pp.265~272 (2015)
- Olmedillas-Lopez S, "Current and emerging applications of droplet digital PCR in oncology", Mol Diagn Ther, 21, pp.493~510 (2017)
- Taylor SC, "Droplet Digital PCR versus qPCR for gene expression analysis with low abundant targets : from variable nonsense to publication quality data", Sci Rep, 7, pp.2409~ (2017)
- Kim SS, "Droplet digital PCR-based EGFR mutation detection with an internal quality control index to determine the quality of DNA", Sci Rep, 8, pp.543~ (2018)
- Kim S, "Deamination effects in formalin-fixed, paraffin-embedded tissue samples in the era of precision medicine", J Mol Diagn, 19, pp.137~146 (2017)
- Do H, "Sequence artifacts in DNA from formalinfixed tissues : causes and strategies for minimization", Clin Chem, 61, pp.64~71 (2015)
- Vasan N, "Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kalpha inhibitors", Science, 366, pp.714~723 (2019)
- Martinez-Saez O, "Frequency and spectrum of PIK3CA somatic mutations in breast cancer", Breast Cancer Res, 22, pp.45~ (2020)
- Pierobon M, "Enrichment of PI3K-AKT-mTOR pathway activation in hepatic metastases from breast cancer", Clin Cancer Res, 23, pp.4919~4928 (2017)